Article information
Full text is only aviable in PDF
REFERENCES
[1]
Global Initiative for Chronic Obstructive Lung Disease.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.
[2]
PM Calverley, PS Burge, S Spencer, JA Anderson, PW Jones.
Bronchodilator reversibility testing in chronic obstructive pulmonary disease.
Thorax, 58 (2003), pp. 659-664
[3]
A Corsico, M Milanese, S Baraldo, et al.
Small airway morphology and lung function in the transition from normality to chronic airway obstruction.
J Appl Physiol, 95 (2003), pp. 441-447
[4]
RH Moreno, JC Hogg, PD Pare.
Mechanics of airway narrowing.
Am Rev Respir Dis, 133 (1986), pp. 1171-1180
[5]
NJ Gross.
Tiotropium bromide.
Chest, 126 (2004), pp. 1946-1953
[6]
JL Izquierdo Alonso, R Malo de Molina.
Otras formas de broncodilatación.
Arch Bronconeumol, 40 (2004), pp. 23-29
[7]
ER Sutherland, RM Cherniack.
Management of chronic obstructive pulmonary disease.
N Engl J Med, 350 (2004), pp. 2689-2697
[8]
R Casaburi, DA Mahler, PW Jones, et al.
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.
Eur Respir J, 19 (2002), pp. 217-224
[9]
DE O'Donnell, T Fluge, F Gerken, et al.
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.
Eur Respir J, 23 (2004), pp. 832-848
[10]
B Celli, R ZuWallack, S Wang, S Kesten.
Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.
Chest, 124 (2003), pp. 1743-1748
[11]
V Brusasco, R Hodder, M Miravitlles, et al.
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Thorax, 58 (2003), pp. 399-404
[12]
W Vincken, JA van Noord, APM Greefhorst, et al.
Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium.
Eur Respir J, 19 (2002), pp. 209-216
[13]
D Dusser, ML Bravo, P Iacono, on behalf the MISTRAL study group.
The effect of tiotropium on exacerbations and airflow in patients with COPD.
Eur Respir J, 27 (2006), pp. 547-555
[14]
DE Niewoehner, K Rice, C Cote, D Paulson, JA Cooper Jr, L Korducki, et al.
Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Ann Intern Med, 143 (2005), pp. 317-326
[15]
RG Barr, J Bourbeau, CA Camargo, FSF Ram.
Tiotropio inhalado para la enfermedad pulmonar obstructiva crónica estable (Translated Cochrane review).
La Biblioteca Cochrane Plus, Update Software Ltd., (2006),
[16]
RG Barr, J Bourbeau, CA Camargo, FSF Ram.
Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis.
Thorax, 61 (2006), pp. 854-862
[17]
A Anzueto, D Tashkin, S Menjoge, S Kesten.
One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium.
Pulm Pharmacol Ther, 18 (2005), pp. 75-81
[18]
Chronic obstructive pulmonary disease.
National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Managing stable COPD.
Thorax, 59 (2004), pp. 39-130
[19]
JB Oostenbrink, MP Rutten-van Mölken, MJ Al, JA van Noord, W Vincken.
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
Eur Respir J, 23 (2004), pp. 241-249
[20]
M Friedman, SS Menjoge, SF Anton, S Kesten.
Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
Pharmacoeconomics, 22 (2004), pp. 741-749
[21]
P de Lucas Ramos, M Miravitlles, JM Rodríguez González-Moro, J de Miguel Díez, S López Martín, G Sánchez Muñoz.
Análisis de costeefectividad del empleo de tiotropio versus ipratropio en el tratamiento de los pacientes con enfermedad pulmonar obstructiva crónica.
Pharmacoeconomics Spanish Research Articles, 1 (2004), pp. 123-130
[22]
AJ García Ruiz, F Leiva Fernández, F Martos Crespo.
Análisis del coste-eficacia del tiotropio frente al ipratropio y salmeterol.
Arch Bronconeumol, 41 (2005), pp. 242-248
[23]
JA van Noord, JL Aumann, E Janssens, JJ Smeets, J Verhaert, B Disse, et al.
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
Eur Respir J, 26 (2005), pp. 214-222
[24]
M Cazzola, P Noschese, A Salzillo, et al.
Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients.
Respir Med, 99 (2005), pp. 524-528
[25]
A Baloira Villar, C Vilarino Pombo.
Eficacia broncodilatadora de la asociación de salmeterol y tiotropio en pacientes con EPOC.
Arch Bronconeumol, 41 (2005), pp. 130-134
[26]
DE O'Donnell.
Is sustained pharmacologic lung volume reduction now possible in COPD?.
Chest, 129 (2006), pp. 501-503
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
